Galapagos just disclosed new good results of its Phase 2B study in rheumatoid arthritis. The drug could be a lifesaver for AbbVie, which is facing patent lost of its most profitable drug Humira.
Mechelen, Belgium-based Galapagos NV announced today that at week 24, patients treated with the selective JAK1 inhibitor filgotinib showed further improvement in signs and symptoms of rheumatoid arthritis activity. Impressing results are showing that up to 64% of patients achieved remission or low disease state after 24 weeks of treatment, with good tolerability of the treatment.
Galapagos’ filgotinib is an oral treatment, selectively inhibiting the activity of the Janus kinase 1. By doing so, the inhibitor blocks cytokine signaling and related inflammation that lead to diseases such as rheumatoid arthritis or Crohn’s disease. In this study, Galapagos’ treatment has been tested in 594 patients with moderate to severe rheumatoid arthritis who showed an inadequate response to the standard treatment methotrexate.
More than the goose that laid the golden eggs for Galapagos, filgotinib could be a critical asset for the American giant AbbVie.